BIOA three-lens brief
Evidence-based stock research on BIOA. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
Price down 5.67% in the last session — a material single-day move. · 50-day MA below 200-day MA (death-cross regime); price below both.
- Price down 5.67% in the last session — a material single-day move.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- RSI at 30 — technically oversold.
- Underperforming SPY by 64.9pp over 30 days.
- P/E of 1.4 — trading at a value multiple.
BIOA closed at $8.65 (-5.67%) as of 2026-09-11. Market cap: $397.01M. P/E (trailing) 1.4. Price is below the 50-day MA and below the 200-day MA. Positives: p/E of 1.4 — trading at a value multiple.. Concerns: price down 5.67% in the last session — a material single-day move.; 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $2.45M, net income -$26.10M, free cash flow -$58.07M.
Why three lenses on BIOA, not one.
A single reasoning model has blind spots it doesn’t know about. We examine BIOAacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/BIOA" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath BIOA brief"></iframe>